Hi, John. You wrote, "For this reason, I don’t believe the effect of increased efficacy with longer time between doses will be generalizable to other vaccine designs. It might apply to other viral vector-type COVID-19 vaccines, though, like the Johnson and Johnson vaccine. Maybe we’ll find out in future studies." J&J is actually running ENSEMBLE 2, a Phase 3 study of their vaccine using two doses, with dose 2 administered on Day 57 (counting from first shot as Day 1). Results due pretty soon, IIRC. Took longer than ENSEMBLE (single dose), presumably because of that two-month wait.
https://health.mountsinai.org/blog/researchers-identify-promising-new-antiviral-drug-for-covid-19/?j=12009&sfmc_sub=45056&l=15_HTML&u=213847&mid=100003651&jb=45
Hi, John. You wrote, "For this reason, I don’t believe the effect of increased efficacy with longer time between doses will be generalizable to other vaccine designs. It might apply to other viral vector-type COVID-19 vaccines, though, like the Johnson and Johnson vaccine. Maybe we’ll find out in future studies." J&J is actually running ENSEMBLE 2, a Phase 3 study of their vaccine using two doses, with dose 2 administered on Day 57 (counting from first shot as Day 1). Results due pretty soon, IIRC. Took longer than ENSEMBLE (single dose), presumably because of that two-month wait.